Clinical OMICS

MAR-APR 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 43 of 47

42 Clinical OMICs March/April 2017 Precision Medicine Children's Minnesota, the largest pediatric health system in the U . S . , has announced it will use the diagnostic platform of RPRD (Right Person Right Drug) Diagnostics in a collabo- ration designed to advance pharmacogenomic testing . "Our intention is to begin using this testing platform within the clinical programs that make the most sense . Right now, that means focusing on our cancer and blood disorders clinic and the neurology-psychology practice," Nancy Men- delsohn, M . D . , senior medical director of specialty care at Children's, told Clinical OMICs . Genes targeted by drugs for these diseases or conditions are expected to be a main focus at first, expanding over time into other relevant indications, RPRD founder and CEO Ulrich Broeckel, M . D . , said . Under the collaboration, whose value was not disclosed, DNA samples from Children's patients will be sent to RPRD, which will perform testing using Affymetrix PharmacoScan. The platform can analyze 4,627 markers within 1,191 genes of known pharmacogenomic value, at prices the company calls competitive with single-gene tests . "While RPRD Diagnostics might report on a subset of genes as a panel test, the overarching goal is to utilize the full set of genes," Dr. Broeckel said. Test results with interpretation will be sent to Children's for integration in the patient's electronic medical record . Results will be available for physicians through the EMR and accompanying clinical decision support systems . RPRD offers healthcare providers comprehensive phar- macogenomic testing and analysis services designed to advance precision medicine in routine clinical practice . It also offers custom genotyping panels tailored to the spe- cialties of providers, and develops new tests for novel gene variants . "As novel research findings become available, we will custom design tests based on need," Dr. Broeckel said. Last year, Dr . Mendelsohn said, Children's launched a pilot pharmacogenomics clinical service for approximately 50 patients . Results were positive and allowed for the iden- tification of altered drug metabolism impacts for 90% of patients enrolled . "Our genomic medicine team has long held the desire to further improve outcomes through pharmacogenomics, and RPRD Diagnostics's deep expertise and strong testing plat- form were deemed an ideal fit for our needs," Dr. Mendel- sohn said . —Alex Philippidis RPRD, Children's Minnesota Partner on PGx Testing WuXi NextCODE Names Hannes Smarason as CEO Contract genomics organization WuXi NextCODE, a WuXi AppTec company, has appointed Hannes Sma- rason as company CEO, and also announced the promotions of senior vice presidents John Long and Alex Fowkes as CFO, and COO, respectively. Smarason co-founded NextCODE Health in 2013 as a spinout from deCODE genetics. He oversaw its acquisition by WuXi AppTec in 2015, and its merger with the WuXi Genome Center to create WuXi Next- CODE. He has served as COO since the merger. "WuXi NextCODE is executing on its vision to enable anyone to use the genome to advance health and wellness worldwide," said Dr. Ge Li, founder and chairman of WuXi AppTec group and chairman of WuXi Nex- tCODE. "It is also positioning itself as the data management platform at the heart of the genomics revolution and what may become the world's largest data ecosystem. Hannes, John and Alex have the breadth of vision and proven executive capabilities to carry out this strategy and advance the company to the next level." freemixer / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2017